We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

90 hedge funds and large institutions have $492M invested in Stoke Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.4% less ownership

Funds ownership: 55.07% → 52.67% (-2.4%)

7% less funds holding

Funds holding: 97 → 90 (-7)

13% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 30

28% less capital invested

Capital invested by funds: $680M → $492M (-$188M)

47% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 15

55% less call options, than puts

Call options by funds: $336K | Put options by funds: $745K

Holders
90
Holders Change
-7
Holders Change %
-7.22%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
26
Reduced
30
Closed
15
Calls
$336K
Puts
$745K
Net Calls
-$409K
Net Calls Change
-$1.04M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.03M
3
TCM
Tekla Capital Management
Massachusetts
+$2.77M
4
Millennium Management
Millennium Management
New York
+$1.53M
5
HS
HighVista Strategies
Massachusetts
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$22.6M
2
SFM
Sphera Funds Management
Israel
-$7.85M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$3.42M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$3.26M
5
BlackRock
BlackRock
New York
-$2.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
QT
76
Quantbot Technologies
New York
$30K +$27.9K +1,000 +500%
Zurich Cantonal Bank
77
Zurich Cantonal Bank
Switzerland
$25K -$251 -9 -0.9%
PCM
78
Penserra Capital Management
California
$21K +$139 +5 +0.6%
Canada Life
79
Canada Life
Manitoba, Canada
$19K – – –
EWM
80
Endurance Wealth Management
Rhode Island
$18K – – –
OSAM
81
O'Shaughnessy Asset Management
Connecticut
$16K – – –
SOW
82
State of Wyoming
Wyoming
$12K -$8.31K -298 -38%
Osaic Holdings
83
Osaic Holdings
Arizona
$8K – – –
Simplex Trading
84
Simplex Trading
Illinois
$7K – – –
CFGS
85
Concourse Financial Group Securities
Alabama
$5K – – –
First Manhattan
86
First Manhattan
New York
$3K – – –
Daiwa Securities Group
87
Daiwa Securities Group
Japan
$3K +$1.62K +58 +85%
RE
88
RBC Europe
United Kingdom
$2.34K – – –
IRC
89
Investors Research Corp
Georgia
$1K – – –
S
90
SignatureFD
Georgia
$1K +$920 +33 New
PA
91
Perceptive Advisors
New York
– -$22.6M -671,978 Closed
SFM
92
Sphera Funds Management
Israel
– -$7.85M -233,135 Closed
B
93
Bailard
California
– -$1.46M -43,300 Closed
PP
94
PDT Partners
New York
– -$860K -25,554 Closed
JF
95
Jump Financial
Illinois
– -$343K -10,200 Closed
TI
96
Trexquant Investment
Connecticut
– -$301K -8,949 Closed
Principal Financial Group
97
Principal Financial Group
Iowa
– -$282K -8,365 Closed
D.E. Shaw & Co
98
D.E. Shaw & Co
New York
– -$240K -7,143 Closed
State Board of Administration of Florida Retirement System
99
State Board of Administration of Florida Retirement System
Florida
– -$222K -6,593 Closed
Squarepoint
100
Squarepoint
New York
– -$219K -6,495 Closed
1 2 3
4
5

STOK Hedge Fund Activity: Q3 2021 in Review

90 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2021, worth a combined $492M — down 28% from $680M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of STOK and 8 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 26 added.

The largest buyer was Fidelity Investments, adding an estimated $8.96M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $22.6M sold.

  • 90 institutional investors held Stoke Therapeutics (STOK) as of Q3 2021, down from 97 in Q2 2021.
  • Funds reported $492M of Stoke Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
  • 8 funds opened new Stoke Therapeutics positions in Q3 2021 and 15 closed out, a net change of -7 holders.
  • The largest Stoke Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $8.96M added.
  • The largest Stoke Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $22.6M sold.

Based on aggregated 13F filings for Q3 2021.